A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide

British Journal of Cancer

Volumn 74, Issue 11, 1996, Pages 1821-1827

  Weaver, A ^a   Wrigley, E ^a   Watson, A ^a   Chang, J ^a   Collins, C D ^a   Jenkins, B ^b   Gill, C ^b   Pettengell, R ^a   Dexter, T M ^c   Testa, N G ^c   Crowther, D ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b AMGEN LTD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Chemotherapy; Dose intensity; Filgrastim; Mobilisation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; BLOOD CELL COUNT; BONE PAIN; CANCER CHEMOTHERAPY; CELL MOTILITY; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RASH; STEM CELL; THROMBOCYTE COUNT;

EID: 10544241546     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.637     Document Type: Article

References (20)

1. ANDREWS R, BARTELMEZ S, KNITTER GH, MYERSON D, BERNSTEIN ID, APPELBAUM FR AND ZSEBO KM. (1992). A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34 colony-forming cell types in blood and marrow of baboons. Blood, 80, 920-927.
2. BELLA M, COCCONI G, LOTTICI R, LEONARDI F, CECI G, PASSALACQUA R, DI BLASIO B, BORDI C, BOSCOTTINI B, MELPIGNANO M, DE BIASI D, FINARDI C AND BACCHI M. (1994). Mature results of a prospective randomised trial comparing two different dose intensive regimens of cisplatin in advanced ovarian carcinoma. Ann. Oncol., 5, (suppl.8), 2 (abstract).
3. CALVERT AH, NEWELL DR, GUMBRELL LA, O'REILLY S, BURNELL M, BOXALL FE, SIDDIK ZH, JUDSO JR, GORE ME AND WILTSHAW E. (1989). Carboplatin dosage; Prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7, 11: 1748-1756.
4. CALVERT AH, LIND MJ, GHAZAL-ASWAD S, GUMBRELL L, MILLWARD MJ, BAILEY NP, DORE-GREEN F, CHAPMAN F, SIMMONS D AND PROCTER M. (1994). Carboplatin and granulocyte colony-stimulating factor as first line treatment for epithelial ovarian cancer: A phase I dose-intensity escalation study. Semin. Oncol., 21, (suppl.12), 1-6.
5. COLOMBO N, PITTELLI MR, PARMA G, MARZOLA M, TORRI W AND MANGIONI C. (1993). Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): a randomised study of conventional dose (DC) vs dose-intensive (DI) cisplatin monochemotherapy. Proc. Am. Soc. Clin. Oncol., 12, 255.
6. DUHRSEN U, VILLEVAL J-L, BOYD J, MORSTYN G AND METCALF D. (1988). Effects of recombinant human granulocyte colony-stimulating factor on hemopoietic cells in cancer patients. Blood, 72, 2074-2079.
7. FEREMANS W, LE-MOINE F, RAVOET C, LAMBERMONT M, BASTIN G, DELVILLE JP, PRADIER O, DUPONT E AND CAPEL P. (1994). Optimal blood stem cell mobilisation using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. Am. J. Hematol., 47 (2), 135-138.
8. GIANNI AM, SIENA S, BREGNI M, TORELLA C, STERN AC, PILERI A AND BONNADONNA G. (1989). Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet, 2, 580.
9. HRYNIUK W. (1988). The importance of dose intensity in outcome of chemotherapy. In Important Advances in Oncology. Hellman S and Rosenberg S. (eds). pp. 121-141. Lippincott: Philadelphia, PA.
10. JUTTNER CA, TO LB, DYSON PG, HAYLOCK DN AND ROBERTS MM. (1992). Comparison of haematological recovery, toxicity and supportive care of autologous PBPC, autologous BM and allogeneic BM transplants. Int. J. Cell Cloning, 10, 160-164.
11. KAYE S, LEWIS C, PAUL J, DUNCAN ID, GORDAN HK, KITCHENER HC, CRUICKSHANK DJ, ATKINSON RJ, SOUKOP M AND RANKIN EM. (1992). Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian carcinoma. Lancet, 340, 329-333.
12. LEVIN L AND HRYNIUK W. (1987). Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol., 5, 756-767.
13. MCGUIRE WP, HOSKINS WJ, BRADY MF, HOMESLEY HD, CLAKE-PEARSON DL. (1992). A phase III trial of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol., 11, 226.
14. MURPHY D, CROWTHER D, RENNISON J, PRENDIVILLE J, RANSON M, LIND M, PATEL U, DOUGAL M, BUCKLEY CH AND TINDALL VR. (1993). A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann. Oncol., 4, 377-383.
15. NGAN HYS, CHOO YC, CHEUNG M, WONG LC, MA HK, COLLINS R, FUNG C, NG CS, WONG V AND HO HC. (1989). Hong Kong Ovarian Carcinoma study group. A randomised study of high dose versus low dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy, 35, 221-227.
16. PARKIN DM, LAARA E AND MUIR CS. (1988). Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer, 41, 184-197.
17. RUSSELL NH, HUNTER A, ROGERS S, HANLEY J AND ANDERSON D. (1993). Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet, 341, 1482.
18. SIENA S, BREGNI M, BONSI L, SKLENAR I, BAGNARA GP, BONNADONNA G AND GIANNI GM. (1991). Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood, 77, 400-409.
19. SOCINSKI MA, ELIAS A, SCHNIPPER L, CANNISTRA SA, ANTMAN KH AND GRIFFIN JD. (1988). Granulocyte- macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet, 1, 1194-1196.
20. + cell counts. Blood, 84, (suppl.1), 2149.